Anzeige
Mehr »
Login
Mittwoch, 30.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Desert Gold Ventures: Diese Goldaktie ist ein TOP-Übernahmekandidat
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
213 Leser
Artikel bewerten:
(1)

The Business Reseach Company: Key Induced Pluripotent Stem Cell (IPSC) Market Trend Adopted By Major Companies To Treat Chronic Diseases - By The Business Research Company

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

LONDON, March 29, 2023 /PRNewswire/ -- As per The Business Research Company's Induced Pluripotent Stem Cell (IPSC) Global Market Report 2023, investment in regenerative medicine research and development is a key trend influencing the induced pluripotent stem cell (IPSC) market. Major companies operating in the induced pluripotent stem cell (IPSC) market are extensively undertaking research and development activities for the development of induced pluripotent stem cells (IPSC) to treat different chronic diseases. For instance, in March 2021, FUJIFILM Corporation, a Japan based multinational conglomerate company operating in medical electronics, biotechnology, and chemicals invested 100 million yen ($0.76 million) into Cuorips Inc, a Japan based biotech venture for developing and commercializing iPSC-based treatment for heart failure.

TBRC Logo

Fujifilm Holdings Corporation is the largest competitor in the induced pluripotent stem cell (IPSC) market, with a 10.4% share of market. Fujifilm Holdings Corporation is a Japan based photography and imaging company. It manufactures imaging solutions which includes photography equipment, supplies and services, optical devices as well as healthcare & material solutions such as healthcare, high-performance materials, graphic systems, recording media, and industrial products.

FUJIFILM Cellular Dynamics's growth strategy focuses on strengthening its cell therapies business through expanding its operational capabilities. For instance, in March 2020, the company began the operation of its new cGMP-compliant-1 iPSC production, at Innovation Facility for Advanced Cell Therapy (i-FACT). The new facility involves in manufacturing and developing induced pluripotent stem cells for therapeutic applications.

Learn More On The Induced Pluripotent Stem Cell (IPSC) Market Report - https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report

According to induced pluripotent stem cell (IPSC) market analysis, the global induced pluripotent stem cell (IPSC) market size will grow from $2.6 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of more than 10%. The global induced pluripotent stem cell (IPSC) market size is then expected to grow to $4.3 billion in 2027 at a CAGR of nearly 10%. Going forward, an increasing prevalence of chronic diseases, growth in genomic projects, development of iPSC-derived disease models, an increasing prevalence of genetic diseases, government initiatives and a rapid increase in technology will drive the induced pluripotent stem cell (IPSC) market growth.

The global induced pluripotent stem cell (IPSC) market is segmented -

1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cells

2) By Application: Academic Research, Drug Development And Discovery, Toxicity Screening, Regenerative Medicine

3) By End-User: Hospitals, Research Laboratories

The top opportunities in these market segments derived cell type will arise in the fibroblasts market, by application will arise in the drug discovery and toxicity studies market, by end-users will arise in research laboratories market, The induced pluripotent stem cell (IPSC) market size will gain the most in the USA at $267.8 million.

Request A Free Sample Of The Induced Pluripotent Stem Cell (IPSC) Market Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=2515&type=smp

The induced pluripotent stem cell (IPSC) market report describes and explains the induced pluripotent stem cell (IPSC) market and covers 2017-2022, termed the historic period, and 2022-2027 termed the forecast period, along with further forecasts for the period 2027-2032. The report evaluates the market across each region and for the major economies within each region.

View More Similar Market Reports:

Stem Cell Global Market Report 2023

https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report

Cell Culture Global Market Report 2023

https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report

Stem Cell Therapy Global Market Report 2023

https://www.thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report

Interested to know more about The Business Research Company?

The Business Research Company has published over 3000+ detailed industry reports, spanning over 3000+ market segments and 60 geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

The World's Most Comprehensive Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users make better strategic decisions.

Contact Information

The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn:https://in.linkedin.com/company/the-business-research-company
Twitter:https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog:https://blog.tbrc.info/
Healthcare Blog:https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Logo: https://mma.prnewswire.com/media/1751581/tbrc_logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/key-induced-pluripotent-stem-cell-ipsc-market-trend-adopted-by-major-companies-to-treat-chronic-diseases--by-the-business-research-company-301784417.html

© 2023 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.